We are international
• treatment options TEXT SIZE   
imf funded research    back

Specific Inhibitors of Ubiquitin-Dependent Proteasomal Degradation
David Smith, PhD
Department of Biochemistry
West Virginia University
Morgantown, West Virginia, USA

Velcade, an inhibitor of the 20S proteasome, is a first line therapy for Multiple Myeloma. However, it’s toxic to patients and thus its effectiveness is limiting and patients often relapse. These toxicities likely develop because the 20S proteasome is an essential enzyme that regulates most cellular process. Recently, we’ve discovered a new way to inhibit the proteasome—by blocking its regulator. Drugs that work in this new way will block some of its functions, but not all, and so we hope that this new type of proteasome inhibitor may be less toxic and thus more effective for treating Multiple Myeloma.

 related articles